CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 1.96 HKD -1.51% Market Closed
Market Cap: 2.5B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CStone Pharmaceuticals
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Accounts Payable
ÂĄ245m
CAGR 3-Years
177%
CAGR 5-Years
118%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Payable
ÂĄ3.7B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Payable
ÂĄ299.9m
CAGR 3-Years
39%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accounts Payable
ÂĄ1.1B
CAGR 3-Years
25%
CAGR 5-Years
85%
CAGR 10-Years
39%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Payable
ÂĄ16.3B
CAGR 3-Years
41%
CAGR 5-Years
47%
CAGR 10-Years
91%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Payable
ÂĄ44.7m
CAGR 3-Years
113%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
2.5B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
3.12 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Accounts Payable?
Accounts Payable
245m CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Accounts Payable amounts to 245m CNY.

What is CStone Pharmaceuticals's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
118%

Over the last year, the Accounts Payable growth was -29%. The average annual Accounts Payable growth rates for CStone Pharmaceuticals have been 177% over the past three years , 118% over the past five years .

Back to Top